Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28097052 | 0.86 | CHRM2 (0.30) | CHRM2CHRM1CHRM3LMNAHSD17B10 | |
| SCHEMBL28181637 | 0.82 | CHRM2 (0.35) | CHRM2CHRM1CHRM3 | |
| SCHEMBL28803663 | 0.82 | CHRM2 (0.35) | CHRM2CHRM1CHRM3 | |
| SCHEMBL27695299 | 0.82 | CHRM2 (0.35) | CHRM2CHRM1CHRM3 | |
| SCHEMBL27680770 | 0.81 | LMNA (0.31) | LMNAHSD17B10 | |
| SCHEMBL27611213 | 0.79 | LMNA (0.40) | LMNAHSD17B10 | |
| SCHEMBL27593048 | 0.79 | LMNA (0.40) | LMNAHSD17B10 | |
| SCHEMBL27593233 | 0.79 | LMNA (0.30) | LMNAHSD17B10 | |
| SCHEMBL27593046 | 0.79 | LMNA (0.40) | LMNAHSD17B10 | |
| SCHEMBL27593232 | 0.79 | LMNA (0.30) | LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | CHRM2 4773/4885CHRM1 4736/4885CHRM3 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.